You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
AKT Inhibitor IV New
Biological Activity for AKT Inhibitor IV
AKT Inhibitor IV promotes hyperphosphorylation of Akt (Protein kinase B), decreases phosphorylation of Akt substrates, and inhibits FOXO1a nuclear export (IC50 = 625 nM in PTEN-null cells). AKT Inhibitor IV inhibits the proliferation of several cells lines (IC50 values are <1.25 μM, 320 - 670 nM and 340 nM for 786-O, HeLa and Jurkat cells, respectively). This compound also displays broad antiviral activity against negative-stranded RNA viruses; inhibits replication of parainfluenza virus 5 (PIV5) in HeLa cells (IC50 = 520 nM). In HeLa cells, AKT Inhibitor IV accumulates in mitochondria, disrupting morphology and increasing ROS production. At high concentrations (10 μM), AKT Inhibitor IV activates the unfolded protein response and apoptosis in HEK293T cells.
AKT Inhibitor IV is weakly fluorescent upon irradiation with UV light (excitation/emission maxima λ ~ 388/460; quantum yield = 0.0016).
Technical Data for AKT Inhibitor IV
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for AKT Inhibitor IV
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for AKT Inhibitor IV
The following data is based on the product molecular weight 614.54. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.63 mL||8.14 mL||16.27 mL|
|5 mM||0.33 mL||1.63 mL||3.25 mL|
|10 mM||0.16 mL||0.81 mL||1.63 mL|
|50 mM||0.03 mL||0.16 mL||0.33 mL|
Product Datasheets for AKT Inhibitor IV
References for AKT Inhibitor IV
References are publications that support the biological activity of the product.
Kau et al (2003) A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 4 463 PMID: 14706338
Sun et al (2011) Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV. J.Med.Chem 54 1126 PMID: 21319800
Meinig & Peterson (2015) Anticancer/antiviral agent Akt inhibitor-IV massively accumulates in mitochondria and potently disrupts cellular bioenergetics. ACS.Chem.Biol. 10 570 PMID: 25415586
If you know of a relevant reference for AKT Inhibitor IV, please let us know.
View Related Products by Target
Keywords: AKT Inhibitor IV, AKT Inhibitor IV supplier, AKTIV, Akt, inhibitor, IV, Chembridge, 5233705, anticancer, antiviral, 681281-88-9, (Protein, Kinase, B), Non-selective, Antivirals, 5985, Tocris Bioscience
Citations for AKT Inhibitor IV
Citations are publications that use Tocris products.
Currently there are no citations for AKT Inhibitor IV. Do you know of a great paper that uses AKT Inhibitor IV from Tocris? Please let us know.
Reviews for AKT Inhibitor IV
There are currently no reviews for this product. Be the first to review AKT Inhibitor IV and earn rewards!
Have you used AKT Inhibitor IV?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.